Department of Microbiology and Biochemistry, Faculty of Pharmacy, Al Sham Private University, Syria
*Corresponding author: Rim M Harfouch, Department of Microbiology and Biochemistry, Faculty of Pharmacy, Al Sham private university, Latakia, Syria
Submission: May 05, 2022; Published: July 26, 2022
ISSN: 2578-0190 Volume6 Issue1
The 2019 coronavirus disease (COVID-19) presents with a large variety of clinical manifestations ranging from asymptomatic carrier state to severe respiratory distress, multiple organ dysfunction and death. While it was initially considered primarily a respiratory illness, rapidly accumulating data suggests that COVID-19 results in a unique, profoundly prothrombotic milieu leading to both arterial and venous thrombosis. Consistently, elevated D-dimer level has emerged as an independent risk factor for poor outcomes, including death. The pathophysiology underlying the hyper-coagulation state is poorly understood. However, a growing body of data suggests that the initial events occur in the lung. A severe inflammatory response, originating in the alveoli, triggers a dysfunctional cascade of inflammatory thrombosis in the pulmonary vasculature, leading to a state of local coagulopathy. This is followed by a generalized hyper-coagulation state that results in and microvascular thrombosis. Of concern, is the observation that anticoagulation may be inadequate in many circumstances, highlighting the need for alternative or additional therapies. Numerous ongoing studies investigating the pathophysiology of the COVID-19 associated coagulopathy may provide mechanistic insights that can direct appropriate interventional strategies.
Keywords:COVID-19; D-dimer; Hyper-coagulation; Predictive marker